The concern of generic rivalry has long loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of related drug ventures. While initial periods saw impressive returns, Pharma the patent end has opened the door for cheaper copies, likely diminishing earnings and creating a significant hazard for stakeholders s